Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost every other dialysis patient dies from cardiovascular complications. Fresenius Medical Care supports nephrologists worldwide in minimizing their patients’ risks for cardiovascular morbidity and mortality.
HighVolumeHDF therapy as well as innovative membranes like Helixoneplus and modern monitoring features like the Blood Volume Monitor, together with ultrapure dialysis fluid, help minimize CVD risk factors and significantly improve the quality and efficacy of hemodialysis therapy.
Click here to experience the Augmented Reality (AR) and Virtual Reality (VR) of the 5008S CorDiax device.
With our portfolio for Peritoneal dialysis and Home hemodiaysis you can be certain of having everything you need so as to optimize the outcomes for your patients while meeting their personal preferences.
Dialysis largely replicates the functions of the kidneys in patients with chronic kidney failure. Hemodialysis and peritoneal dialysis take over the key tasks of the kidneys, removing waste materials, toxins, excess salt and fluids from the body.
Dialysis treatment does not entirely replace all the functions of the kidneys, meaning that patients almost always need to take certain medications regularly. These include antihypertensive treatments, drugs for lowering phosphate levels in the blood, vitamins and drugs that boost the production of red blood cells to prevent anemia.
Xenios AG — a Fresenius Medical Care company – is a pioneer in extracorporeal heart and lung support, dedicated to improving patients’ lives with high-quality products and application-related service excellence.
Learn more on our Xenios website
At Fresenius Medical Care we are committed to addressing individual needs in the treatment of children on renal replacement therapy. Children vary in age, body size and underlying medical condition, and they all come from different family situations: There are many factors which influence the choice of the right treatment for a child.
Fresenius Medical Care offers a broad range of dialysis products for each individual situation and therapy fulfilling the highest quality standards in the areas of:
Acute and chronic peritoneal dialysis
Acute kidney injury
Fresenius Kidney Care, the dialysis care services division of Fresenius Medical Care, is striving to set the standard in the healthcare industry by delivering care that demonstrates improvements in the quality of life for every patient every day.
We are known for our ability to successfully partner and work with physicians across the region. Our clinical care standards, safety procedures and advanced clinical research give physicians the reassurance that their patients are in caring and competent hands.
With our performance management systems, we strive to improve patients’ medical outcomes while optimizing operational performances of clinics, taking all dimensions of patient care into account.
Renal IT provides integrated software solutions supporting chronic kidney disease care in a more efficient, reliable, cost effective way: to manage in center, acute or home therapies.
Renal IT provides decision support and analytical insights into therapy data. As a one-stop shop, Fresenius Medical Care provides a full range of software, hardware, installation and support.
Fresenius Medical Care is highly committed to supporting the advancement of genuine medical/scientific education of healthcare professionals in relevant therapeutic areas, and therefore contributes to the improvement of healthcare standards and enhanced patient care.
At Fresenius Medical Care Singapore, our vision is ‘Creating a future worth living for patients worldwide, every day’. To achieve this, the Fresenius Kidney Care Academy was established to support nurses’ knowledge and skills development in the clinical specialty of dialysis- nephrology nursing, from novice to competent/expert level of practice.
To find out more, click here.